ABUS · Nasdaq · CIK 0001447028

Arbutus Biopharma Corp

Arbutus Biopharma Corp’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $14.1M and net income of -$33.5M, according to its XBRL data on EDGAR. Its EDGAR record lists 13 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$14.1M
Net income, FY2025
-$33.5M
Form 4 filings on record, past 12 months
13

Company overview

Legal name (as filed)
Arbutus Biopharma Corp
Ticker
ABUS
SEC Central Index Key (CIK)
0001447028
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
WARMINSTER, PA
State or country of incorporation
British Columbia, Canada
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2744 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Arbutus Biopharma Corp’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$11.0MFY2021$39.0MFY2022$18.1MFY2023$6.2MFY2024$14.1MFY2025
Net income
-$76.2MFY2021-$69.5MFY2022-$72.8MFY2023-$69.9MFY2024-$33.5MFY2025
ABUS annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$11.0M$39.0M$18.1M$6.2M$14.1M
Net income-$76.2M-$69.5M-$72.8M-$69.9M-$33.5M
Diluted EPS-$0.83-$0.46-$0.44-$0.38-$0.17
Total assets$204.5M$195.4M$144.4M$131.7M$94.6M
Cash and equivalents$109.3M$30.8M$26.3M$36.3M$18.0M

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ABUS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 23, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 12, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 22, 20268-KOther events· period Oct 20, 2026Document · Index
Apr 14, 2026DEF 14ADefinitive proxy statement· period May 26, 2026Document · Index
Mar 27, 201320-FAnnual report of a foreign private issuer· period Dec 31, 2012Document · Index
Mar 21, 20146-KReport of a foreign private issuer· period Mar 20, 2014Document · Index

Recent SEC filings

The 40 newest documents filed by or about Arbutus Biopharma Corp, by form type:

4 ×118-K ×10SCHEDULE 13G/A ×5SCHEDULE 13D/A ×3SC TO-I/A ×210-Q ×2SCHEDULE 13G ×1SC TO-I ×1SC TO-C ×1S-8 ×1DEFA14A ×1DEF 14A ×110-K ×1
ABUS recent filings
FiledFormWhat it isOriginal
Oct 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 22, 20268-KOther events· period Oct 20, 2026Document · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 7, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 5, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 1, 2026SC TO-I/ASC TO-I/ADocument · Index
Sep 30, 2026SC TO-I/ASC TO-I/ADocument · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 18, 2026Document · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 18, 2026Document · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 18, 2026Document · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 18, 2026Document · Index
Sep 4, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 24, 2026SC TO-ISC TO-IDocument · Index
Aug 21, 2026SC TO-CSC TO-CDocument · Index
Aug 21, 20268-KOther events· period Aug 21, 2026Document · Index
Aug 12, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 12, 20268-KResults of operations· period Aug 12, 2026Document · Index
Aug 12, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 16, 20268-KAgreement terminated; Director or officer change; Other events· period Jul 15, 2026Document · Index
Jun 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 8, 2026Document · Index
Jun 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 8, 2026Document · Index
Jun 5, 2026S-8Registration of employee benefit plan securitiesDocument · Index
May 27, 20268-KDirector or officer change; Shareholder vote results· period May 26, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 13, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 13, 20268-KResults of operations· period May 13, 2026Document · Index
Apr 28, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Apr 15, 20268-KOther events· period Apr 14, 2026Document · Index
Apr 14, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 14, 2026DEF 14ADefinitive proxy statement· period May 26, 2026Document · Index
Apr 13, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Mar 23, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 23, 20268-KResults of operations· period Mar 23, 2026Document · Index
Mar 3, 20268-KMaterial agreement; Other events· period Mar 3, 2026Document · Index
Feb 20, 20268-KOther events· period Feb 17, 2026Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index

Insider filing activity

13 Form 4 filings appear in Arbutus Biopharma Corp’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Pennsylvania

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001447028 and XBRL company facts. Arbutus Biopharma Corp on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.